Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, in Combination With Pembrolizumab in Subjects With Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-containing Regimens

Next Previous
X
Search
Trial Profile

An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, in Combination With Pembrolizumab in Subjects With Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-containing Regimens

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Nadunolimab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms CIRIFOUR
  • Sponsors Cantargia

    • Most Recent Events

    • 13 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2022 Status changed from recruiting to active, no longer recruiting.
    • 19 Oct 2022 As per CT.gov Outcome Measures, Arms and Interventions, Study Status, Study Identification, Eligibility, Study Design and Study Description has been amended

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top